NRD
ABCL icon

Nebula Research & Development’s AbCellera Biologics ABCL Stock Holding History

Nebula Research & Development’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-89,496
Closed -$578K – 474
2023
Q2 		$578K Buy
+89,496
New +$611K 0.44% 106

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Nebula Research & Development's ABCL Position: Q3 2023 in Review

Nebula Research & Development sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 89,496 shares — an estimated $578K sold.

Nebula Research & Development first reported a position in ABCL in Q2 2023 and held it in 1 quarter. The position peaked at $578K in Q2 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Nebula Research & Development reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 89,496 AbCellera Biologics shares in Q3 2023, an estimated $578K.
  • Nebula Research & Development first reported a position in AbCellera Biologics in Q2 2023 and held it in 1 quarter.
  • Nebula Research & Development's AbCellera Biologics position peaked at $578K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.